[HTML][HTML] RSV prevention in all infants: which is the most preferable strategy?
…, F Martinon Torres, M Tsolia, S Zielen - Frontiers in …, 2022 - frontiersin.org
… Nirsevimab’s mechanism of action allows for rapid and direct protection with a single
intramuscular dose throughout the RSV season (69, 70). In a Phase IIb study, nirsevimab reduced …
intramuscular dose throughout the RSV season (69, 70). In a Phase IIb study, nirsevimab reduced …
[HTML][HTML] Lung clearance index: evidence for use in clinical trials in cystic fibrosis
…, S Zielen, M Le Bourgeois, C Braggion, S Lever… - Journal of Cystic …, 2014 - Elsevier
The ECFS-CTN Standardisation Committee has undertaken this review of lung clearance
index as part of the group's work on evaluation of clinical endpoints with regard to their use in …
index as part of the group's work on evaluation of clinical endpoints with regard to their use in …
Neurodegeneration in ataxia telangiectasia: what is new? What is evident?
…, M Theis, S Vlaho, R Schubert, S Zielen… - …, 2012 - thieme-connect.com
… ATM does not only regulate DNA repair but also influences various cell cycle checkpoints
such as the G1/S, S, and G2/M phase. In ATM-deficient cells, the G1/S checkpoint shows a loss …
such as the G1/S, S, and G2/M phase. In ATM-deficient cells, the G1/S checkpoint shows a loss …
Montelukast reduces asthma exacerbations in 2-to 5-year-old children with intermittent asthma
H Bisgaard, S Zielen, ML Garcia-Garcia… - American journal of …, 2005 - atsjournals.org
The PREVIA study was designed to investigate the role of montelukast, a leukotriene receptor
antagonist, in the prevention of viral-induced asthma exacerbations in children aged 2 to 5 …
antagonist, in the prevention of viral-induced asthma exacerbations in children aged 2 to 5 …
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
…, J Kirschner, T Schmoller, S Zielen… - The lancet respiratory …, 2019 - thelancet.com
Background Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal
antibody that has been shown to safely reduce exacerbations and improve lung function for …
antibody that has been shown to safely reduce exacerbations and improve lung function for …
Pappataci-Fieber
M Becker, S Zielen, TF Schwarz, R Linde… - Klinische …, 1997 - thieme-connect.com
Sandfly fever virus is known to cause pappataci fever. The sandfly fever virus belongs to the
Genus Phlebovirus (family: Bunyaviridae) and is endemically found in areas of South Europe…
Genus Phlebovirus (family: Bunyaviridae) and is endemically found in areas of South Europe…
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co‐morbid seasonal …
MV Kopp, E Hamelmann, S Zielen… - Clinical & …, 2009 - Wiley Online Library
Background The treatment of allergic asthma by specific immunotherapy (SIT) is hampered
by potential side‐effects. Objective The aim of this study was to study the effect of omalizumab…
by potential side‐effects. Objective The aim of this study was to study the effect of omalizumab…
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis
J Kuehr, J Brauburger, S Zielen, U Schauer… - Journal of Allergy and …, 2002 - Elsevier
Background: Specific immunotherapy (SIT) and treatment with monoclonal anti-IgE antibody
have complementary modes of action. Objective: The purpose of this study was to …
have complementary modes of action. Objective: The purpose of this study was to …
Sublingual immunotherapy provides long‐term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real‐world database analysis
S Zielen, P Devillier, J Heinrich, H Richter, U Wahn - Allergy, 2018 - Wiley Online Library
Background Allergy immunotherapy ( AIT ) is the only treatment for allergic rhinitis ( AR ) and/or
allergic asthma ( AA ) with long‐term efficacy. However, there are few real‐life data on …
allergic asthma ( AA ) with long‐term efficacy. However, there are few real‐life data on …
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study
…, S Wanin, J Just, R Linde, S Zielen… - The Lancet …, 2023 - thelancet.com
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) …
lymphopoietin. The drug has been tested previously in the phase 3 NAVIGATOR (NCT03347279) …